Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Omicron booster

- PMLiVE

Eiger BioPharmaceuticals reports positive phase 3 results for COVID-19 treatment

Peginterferon lambda showed a 51% reduction in hospitalisations or emergency room visits

- PMLiVE

Takeda’s dengue vaccine receives MHRA approval for those aged four years and older

Around 3.9 billion people globally are currently at risk of dengue, a mosquito-borne viral disease

- PMLiVE

NHS urges people yet to receive their COVID-19 booster to come forward

Sunday 12 February is the last day people under 50 years of age who are not considered at risk can receive a booster

- PMLiVE

JCVI recommends autumn COVID-19 vaccine booster for those at highest risk

After high uptake for the initial booster dose in December 2021, further uptake has been low

- PMLiVE

BeiGene’s Brukinsa granted two new marketing authorisations by MHRA

The BTK inhibitor is now approved for chronic lymphocytic leukaemia and marginal zone lymphoma

- PMLiVE

Moderna reports positive phase 3 data for its RSV vaccine for older adults

In the US, RSV causes around 60,000 to 120,000 hospitalisations and 6,000 to 10,000 deaths in older adults each year

- PMLiVE

World Health Organization releases latest set of COVID-19 guidelines

The guidelines include advice on treatments, isolation periods and wearing masks

- PMLiVE

FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine

Preliminary data showed a possible link between the updated vaccine and a higher risk of stroke

- PMLiVE

GSK and CureVac to advance mRNA COVID-19 and flu vaccine candidates

The vaccines produced promising preliminary results in phase 1 trials

- PMLiVE

WHO reports new Omicron subvariant cases detected in 29 countries worldwide

The new Omicron subvariant is spreading rapidly in the US

- PMLiVE

Moderna to acquire OriCiro Genomics for $85m

The deal includes the Japanese DNA supplier’s synthetic biology and enzyme technologies

- PMLiVE

Valneva reports additional data for COVID-19 booster

VLA2001 was well tolerated in participants previously vaccinated with an mRNA vaccine

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links